Call Us: 954-929-4814
Monitors gastrointestinal, pancreatic, liver, and colorectal malignancies.
CA 19-9, a carbohydrate antigen related to Lewis blood group antigen, has been shown to be elevated in serum of some patients with gastrointestinal tumors. CA 19-9, as a tumor marker, is helpful in post-therapeutic monitoring to determine the success of therapy or the development of recurrence when used serially.
CA 19-9 has been reported as positive in 70% to 80% of pancreatic carcinomas, 50% to 60% of gastric cancers, 60% of hepatobiliary cancer, 30% of colorectal cancer, and few lung, breast or prostate cancers.
Serum levels may differentiate pancreatic cancer from pancreatitis. The test may also be positive in patients with non-neoplastic disease, particularly inflammatory disease of the bowel, cirrhosis, and autoimmune conditions including rheumatoid arthritis (33%), systemic lupus erythematosus (32%), and scleroderma (33%).
Methodology: Siemens chemiluminescent assay.
Normal range is less than 35 U/mL.
Values obtained with different assay methods should not be used interchangeably.
CA 19-9 Gastric, Pancreatic Tumor Marker